TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25365032
Drug: Carbohydrate-only placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-only placebo gel (CP) - 21.6 g carbohydrate, 0 mg caffeine
Study: 23728830
Drug: ezetimibe/simvastatin 10/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe/simvastatin 10/20 mg
Study: 23866306
Drug: doubling the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: doubling the baseline statin dose (simvastatin 40 mg or atorvastatin 20 mg)
Study: 19125756
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (120,000 IU each; three doses, administered fortnightly)
Study: 28361822
Drug: Clozapine (200-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine (200-600 mg/day)
Study: 11697576
Drug: Olanzapine (10-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (10-30 mg/day)
Study: 11697576
Drug: Risperidone (8-16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (8-16 mg/day)
Study: 11697576
Drug: Haloperidol (10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (10-40 mg/day)
Study: 11697576
Drug: Sulpiride (600-1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride (600-1600 mg/day)
Study: 11788429
Drug: Drug-free state
Normalized name: CLOZAPINE (GOLDEN STATE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-free state
Study: 8426714
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg triazolam with nitrous oxide
Study: 8426714
Drug: Diazepam (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (mean dose = 19.3 mg)
Study: 23596051
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba (Gb) treatment
Study: 18254761
Drug: IN morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IN morphine 3.75 mg, 7.5 mg, 15 mg, or 30 mg
Study: 18254761
Drug: IV morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV morphine 7.5 mg
Study: 18254761
Drug: IN morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IN morphine 7.5 mg
Study: 18254761
Drug: IN morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IN morphine 15 mg
Study: 11220430
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg x kg(‐1) of oral transmucosal midazolam mixed with strawberry syrup
Study: 11220430
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group received plain syrup 0.08 ml x kg(‐1)
Study: 11220430
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg x kg(‐1) of oral transmucosal midazolam
Study: 8193524
Drug: Matrix controlled
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matrix controlled clonidine transdermal (C‐TD) system
Study: 2419009
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human tissue-type plasminogen activator (rt-PA) 0.75 mg/kg over 90 min
Study: 29451020
Drug: Crizotinib, ceritinib,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crizotinib, ceritinib, and alectinib (previous treatments)
Study: 22396387
Drug: Active conservative
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active conservative treatment for urinary incontinence (UI)
Study: 12049567
Drug: 500 rad
Normalized name: RAD-IFN
DrugBank: Nadofaragene firadenovec (DB17381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 rad (5 Gy) irradiation at 1 minute post-treatment
Study: 12049567
Drug: 500 rad
Normalized name: RAD-IFN
DrugBank: Nadofaragene firadenovec (DB17381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 rad (5 Gy) irradiation at 2 minutes post-treatment
Study: 12049567
Drug: 500 rad
Normalized name: RAD-IFN
DrugBank: Nadofaragene firadenovec (DB17381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 rad (5 Gy) irradiation at 3 minutes post-treatment
Study: 10607256
Drug: Thymosin alpha1
Normalized name: Thymosin alpha1 (human)
DrugBank: Thymalfasin (DB04900)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymosin alpha1 (Talpha1) 1.6 mg, twice weekly for 6 months
Study: 10607256
Drug: Placebo, twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, twice weekly for 6 months
Study: 8578549
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose aspirin (ASA)
Study: 2338114
Drug: cimetidine 600
Normalized name: cimetidine 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cimetidine 600 mg
Study: 9655654
Drug: Transdermal 17‐beta‐oestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17‐beta‐oestradiol (100 microg per 24 h)
Study: 29404725
Drug: Sarilumab 150
Normalized name: SARILUMAB 150MG/1.14ML INJ SYR 1.14ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarilumab 150 mg + MTX
Study: 29404725
Drug: Sarilumab 200
Normalized name: SARILUMAB 200MG/1.14ML INJ SYR 1.14ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarilumab 200 mg + MTX
Study: 27600829
Drug: Sarilumab (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarilumab (both doses)
Study: 31925799
Drug: Tibolone 2.5
Normalized name: tibolone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 2.5 mg daily
Study: 22775481
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined oral E(2) 2 mg/NETA 1 mg daily
Study: 21915249
Drug: Methylcellulose placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylcellulose placebo gel
Study: 18353393
Drug: Ketoconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (400 mg 3 times a day)
Study: 14977479
Drug: High-dose immunosuppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose immunosuppression followed by autologous hematopoietic stem cell transplantation
Study: 14977479
Drug: Mitoxantrone (best
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone (best available therapy)
Study: 11566828
Drug: Voice therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voice therapy for six weeks
Study: 3063046
Drug: Group I:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I: Anesthesia induced with diazepam (94 micrograms x kg‐1), thiopentone (3 mg x kg‐1), and fentanyl (3 micrograms x kg‐1)
Study: 12657406
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion (normal saline)
Study: 29122812
Drug: Metoprolol succinate
Normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol succinate (100 mg/d)
Study: 23388543
Drug: Azathioprine 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine 2.0 to 2.5 mg/kg per day
Study: 23388543
Drug: Mesalamine 4
Normalized name: mesalamine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalamine 4 g/d
Study: 19083482
Drug: L-ornithine (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-ornithine (2000 mg/d for 7 days and 6000 mg/d for 1 day as L-ornithine hydrochloride)
Study: 19083482
Drug: L-ornithine
Normalized name: L-Ornithine
DrugBank: Ornithine (DB00129)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-ornithine
Study: 12180579
Drug: Erythromycin 200
Normalized name: ERYTHROMYCIN 200 mg in 2 g TOPICAL POWDER [API E.M. Erythromycin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 200 mg
Study: 3987183
Drug: Morphine 8
Normalized name: morphine 8 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 8 mg
Study: 11144396
Drug: Cefdinir 14
Normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefdinir 14 mg/kg/day divided twice a day for 5 days
Study: 11144396
Drug: Cefprozil 30
Normalized name: Cefprozil
DrugBank: Cefprozil (DB01150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefprozil 30 mg/kg/day divided twice a day for 10 days
Study: 30096092
Drug: Rifaximin (1100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin (1100 mg/day)
Study: 9416884
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 to 40 mg daily
Study: 15278040
Drug: Mechanical methods
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical methods of hemostasis plus epinephrine injection
Study: 15278040
Drug: Epinephrine injection
Normalized name: epinephrine Injection
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine injection alone
Study: 11804427
Drug: Nafarelin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafarelin (200 microg by nasal route twice a day)
Study: 11804427
Drug: Leuprolide (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide (0.5 mg by subcutaneous route once a day)
Study: 8203940
Drug: Movement therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Movement therapy
Study: 28543914
Drug: Intervention premises
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention premises audited by Environmental Health Practitioners with varying doses (informal advice, written advice, follow-up visits)
Study: 18245177
Drug: D-cycloserine, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-cycloserine, 100 mg
Study: 27725657
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitor (SSRI) treatment
Study: 15231442
Drug: Successful treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Successful treatment with antidepressants
Study: 22932947
Drug: Soft gel
Normalized name: Norvir Soft Gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft gel capsule L-T4 taken with water (proper habit, PH)
Study: 22932947
Drug: Soft gel
Normalized name: Norvir Soft Gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft gel capsule L-T4 taken with coffee ≤ 5 min later (improper habit, IH)
Study: 22932947
Drug: Soft gel
Normalized name: Norvir Soft Gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft gel capsule L-T4 taken with water (PH)
Study: 22932947
Drug: Soft gel
Normalized name: Norvir Soft Gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft gel capsule L-T4 taken with coffee (IH)
Study: 20798662
Drug: 30 min
Normalized name: Goddess Garden SPF 30 Mineral Sunscreen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 min of daily walking at 60% VO(2max) for 1 week in sedentary men (Study 2)
Study: 8501502
Drug: Cyclophosphamide 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 600 mg/m2 + Carboplatin 300 mg/m2
Study: 8501502
Drug: Single-agent Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-agent Carboplatin
Study: 3114783
Drug: Caffeine 32
Normalized name: caffeine 32 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 32 mg
Study: 3114783
Drug: Caffeine 64
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine 64 mg
Study: 3114783
Drug: Caffeine 128
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine 128 mg
Study: 3114783
Drug: Caffeine 256
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine 256 mg
Study: 19764439
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl analgesia
Study: 21543429
Drug: EST expression
Normalized name: SODIUM FLUORIDE 243 mg in 1 g ORAL PASTE, DENTIFRICE [Crest Expressions Scope]
Approvals — FDA: no, EMA: no, PMDA: no
Description: EST expression in subcutaneous adipose tissue
Study: 20415678
Drug: Microsphere adapalene
Normalized name: Adapalene
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microsphere adapalene gel, applied once daily in the evening for 12 weeks
Study: 20415678
Drug: Conventional adapalene
Normalized name: Adapalene
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional adapalene gel, applied once daily in the evening for 12 weeks
Study: 20415678
Drug: Microsphere adapalene
Normalized name: Adapalene
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microsphere adapalene gel
Study: 20415678
Drug: Conventional adapalene
Normalized name: Adapalene
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional adapalene gel
Study: 15155217
Drug: Single-dose voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose voriconazole (3 mg/kg)
Study: 15155217
Drug: Single-dose voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose voriconazole (4 mg/kg)
Study: 15155217
Drug: Multiple-dose voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple-dose voriconazole (6 mg/kg every 12 h on day 1, followed by 3 mg/kg every 12 h on day 2 to day 4 and 4 mg/kg every 12 h on day 4 to day 8)
Study: 15155217
Drug: Voriconazole (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voriconazole (any dosage)
Study: 15155217
Drug: Voriconazole (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voriconazole (4 mg/kg)
Study: 1146748
Drug: 34 g
Normalized name: Droplet Micron Pen Needles 34 g X 3.5 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 34 g protein intake
Study: 1146748
Drug: 57 g
Normalized name: HYDROGEN PEROXIDE 8.57 g in 100 mL TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 57 g protein intake
Study: 1146748
Drug: 88 g
Normalized name: Sutab, 0.225 g-0.188 g-1.479 g oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 88 g protein intake
Study: 27305512
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no gel applied)
Study: 24766062
Drug: Primary care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary care treatment
Study: 19880461
Drug: Specialty care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specialty care treatment
Study: 17005105
Drug: Medication (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (both pramipexole and amantadine)
Study: 9077538
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (Ca-suppl.) with 850 mg of calcium daily for 1 year
Study: 30047245
Drug: 60‐mg iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60‐mg iron and folic acid (IFA)
Study: 30047245
Drug: 20‐mg iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20‐mg iron plus 17 micronutrients in a capsule (MMN)
Study: 30047245
Drug: lipid‐based nutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: lipid‐based nutrient supplement (LNS; 118 kcal) with 20‐mg iron plus 21 micronutrients, protein, and fat
Study: 21449784
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (boceprevir plus peginterferon-ribavirin) for patients with undetectable HCV RNA at week 8
Study: 21449784
Drug: Erythropoietin administration
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin administration in boceprevir-treated patients
Study: 16056097
Drug: 0.2 g
Normalized name: methionine 0.2 gram ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 g acidic oligosaccharides
Study: 16056097
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 0.2 g acidic oligosaccharides and 0.6 g neutral oligosaccharides
Study: 12413624
Drug: 0.75‐mg levonorgestrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75‐mg levonorgestrel 12 h apart (group A)
Study: 12413624
Drug: 1.5‐mg levonorgestrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5‐mg levonorgestrel (group B)
Study: 7652667
Drug: Radiochemotherapy (2‐course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiochemotherapy (2‐course radiation treatment of 60 to 70 Gy total dose in combination with mitomycin C and 5‐fluorouracil)
Study: 2503723
Drug: buserelin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: buserelin (500 micrograms daily subcutaneously) and nilutamide (300 mg daily by mouth)
Study: 412610
Drug: 2% aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% aqueous solution of sodium cromoglycate delivered by a metered dose nasal spray
Study: 23909699
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg intranasal SB‐705498
Study: 8797769
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m2, 3-hour infusion
Study: 8797769
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m2, 6-hour infusion
Study: 8797769
Drug: Paclitaxel 135
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 135 mg/m2, 3-hour infusion
Study: 8797769
Drug: Paclitaxel, 24-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel, 24-hour infusion
Study: 1739926
Drug: High-dose megestrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose megestrol acetate for 1 month
Study: 1739926
Drug: High-dose megestrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose megestrol acetate after crossover from placebo
Study: 27257049
Drug: Sequential Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential Therapy (ST)
Study: 29146042
Drug: Online computerized
Normalized name: FILTER,SUCTION,INLINE #FHBF200S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online computerized cognitive behavioral therapy (MoodGYM) in addition to usual treatment
Study: 19772969
Drug: Metformin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin therapy (425 mg/d for 2 years, then 850 mg/d for 2 years)
Study: 17824901
Drug: Pregabalin, 225
Normalized name: Pregabalin, 225 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin, 225 mg per day
Study: 2406852
Drug: Oral bismuth
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bismuth subsalicylate (600 mg three times daily)
Study: 1418071
Drug: Cimetidine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (800 mg/d)
Study: 2406852
Drug: Oral bismuth
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bismuth subsalicylate
Study: 2548222
Drug: Clonidine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.2 mg)
Study: 16733374
Drug: IFN-alpha induction
Normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha induction (6 MU daily for 2 weeks, then 3 MU daily for 2 weeks, then 3 MU tiw for 20 weeks)
Study: 16733374
Drug: Ribavirin (1-1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin (1-1.2 g daily for 24 weeks)
Study: 9924265
Drug: 20 mmol/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mmol/d Ca supplement (about 40 mmol Ca/d)
Study: 7827299
Drug: Trimethadione (0.9-1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethadione (0.9-1.5 g daily)
Study: 7827299
Drug: Trimethadione treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethadione treatment
Study: 31539060
Drug: CS200 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS200 (200 mg chitosan per kg feed)
Study: 31539060
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 mg chitosan per kg feed)
Study: 30579508
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (details not specified)
Study: 26099138
Drug: Clonidine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (3 µg/kg loading then 0-3 µg/kg/hour)
Study: 26099138
Drug: Midazolam (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (200 µg/kg loading then 0-200 µg/kg/hour)
Study: 22843943
Drug: Dose-dense sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense sequential chemotherapy (DD-CT) with epirubicin followed by paclitaxel every 2 weeks
Study: 22843943
Drug: Conventionally-dosed chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventionally-dosed chemotherapy (CD-CT) with epirubicin and paclitaxel simultaneously every 3 weeks
Study: 22843943
Drug: Breast-conserving surgery
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast-conserving surgery after neoadjuvant chemotherapy
Study: 22843943
Drug: Mastectomy after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mastectomy after neoadjuvant chemotherapy
Study: 19824805
Drug: Propofol 1
Normalized name: propofol 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1 mg.kg(‐1) (group II)
Study: 19824805
Drug: Propofol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1.5 mg.kg(‐1) (group III)
Study: 19824805
Drug: Propofol 2
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2 mg.kg(‐1) (group IV)
Study: 16436011
Drug: Diet and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet and lifestyle intervention including monthly lecture-discussion sessions for 10 months, small group counseling, and educational materials based on WCRF Diet and Health Recommendations for Cancer Prevention.
Study: 10741150
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose therapy with HSCT
Study: 28844307
Drug: Delayed induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed induction protocol (calcium hydroxide as intracanal medication following AAE guidelines)
Study: 21715522
Drug: Jet injection
Normalized name: Jet Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jet injection of insulin aspart (0.2 units/kg body wt)
Study: 21715522
Drug: Conventional pen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional pen injection of insulin aspart (0.2 units/kg body wt)
Study: 15454021
Drug: 0.12% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% chlorhexidine gluconate mouthrinse with oral hygiene instruction (OHI)
Study: 15454021
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline mouthrinse with no oral hygiene instruction (OHI)